SAN DIEGO — A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed.
The hepcidin mimetic rusfertide led to a response rate of 69.2%, defined as maintaining hematocrit